Compare Estee Lauder Companies Inc (EL) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Estee Lauder Companies Inc vs Illumina, Inc. — how do they compare? Estee Lauder Companies Inc trades at $98.05 (market cap $34.17B), while Illumina, Inc. trades at $278.17 (market cap $39.95B). The key difference: Illumina, Inc. is the larger of the two by market cap, and Estee Lauder Companies Inc pays a 1.48% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Estee Lauder Companies Inc for 122 Days and Illumina, Inc. for 83 Days on average.
| EL | ILMN | |
|---|---|---|
Market Cap | $34.17B | $39.95B |
Volume | 3,921,497 | 3,169,503 |
Sector | Consumer Staples | Health |
52-Week High | $119.61 | $293.69 |
52-Week Low | $67.23 | $91.00 |
Typical Hold Time | 122 Days | 83 Days |
Enterprise Value | $39.92B | $41.31B |
Dividend Yield | 1.48% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EL trades at $94.32, down 0.14% on the day, with a neutral technical signal. The stock has beaten earnings estimates for the last three quarters, though annual revenue declined to $14.33B in 2025 with a net loss of $1.13B. Analyst consensus is a Buy with a $103.00 price target, and recent news highlights strategic partnerships in AI and leadership appointments aimed at strengthening brand strategy.
The outlook is cautiously optimistic, supported by earnings beats and positive analyst sentiment, but risks include sustained profitability challenges, high debt levels, and competitive pressures. Upside potential exists if margin improvements and strategic initiatives translate to earnings growth, yet investors must monitor execution on turnaround efforts.
ILMN trades at $264.40, down 1.25% on the day, but remains near its recent 52-week high of $278.99 (Defense World, 2026-10-01). The stock has surged 94.9% year-to-date (Zacks Investment Research, 2026-09-24), supported by strong earnings beats in recent quarters and a bullish technical trend. Fundamentals show a significant turnaround, with 2025 net income reaching $850 million after prior losses, though valuation ratios like a P/E of 49.36 are elevated. The pending inclusion in the S&P 500 (PRNewsWire, 2026-09-04) adds a positive catalyst.
The outlook is positive, driven by sequencing growth, AI integration in genomics, and improved profitability. However, risks include high valuation sensitivity, cost volatility, and competitive pressures in the life sciences sector. Analyst consensus is bullish with a 54% buy rating, but the average price target of $241 suggests limited near-term upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Estee Lauder Companies Inc
Estee Lauder is the world leader in the global prestige beauty market, participating across skincare (56% of fiscal 2022 sales), makeup (26%), fragrance (14%), and haircare (4%) categories, with popular brands such as Estee Lauder, Clinique, MAC, La Mer, Jo Malone, Aveda, Bobbi Brown, Too Faced, Origins, Dr. Jart+, and The Ordinary. The firm operates in 150 countries, with 26% of fiscal 2022 revenue stemming from the Americas, 43% from Europe, the Middle East, and Africa, and 31% from Asia-Pacific. The company sells its products through department stores, travel retail, multi-brand specialty beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
Read more on EL →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
